Biblio Discovery — Demo Discovery Service

1 results for "Edith T. Zemanick"

Showing 1–1 · 0.53 seconds · RSS

  1. Journal Article Full text

    A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele

    Edith T. Zemanick; Jennifer L. Taylor‐Cousar; Jane Carolyn Davies et al.

    American Journal of Respiratory and Critical Care Medicine · 2021 · English · OpenAlex Scopus

    Abstract Rationale Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was shown to be efficacious and safe in patients ≥12 years of age with cystic fibrosis and at least one F508del-CFTR (cystic fibrosis transmembrane conductance regulator) allele, but it has not been evaluated in children